The Drug Regulatory Authority of India has given its approval to a revolutionary new eye drop developed by Mumbai-based Entode Pharmaceuticals Press. This innovative eye drop is designed to address presbyopia, a common age-related condition that leads to difficulty in seeing close objects, particularly as individuals reach their 40s and 60s.
Entitled “PresVu,” this groundbreaking medication is the first of its kind in India and aims to reduce the reliance on reading glasses for individuals suffering from presbyopia. The Drug Controller General of India has granted final approval to ENTOD Pharmaceuticals after a thorough review process by the Subject Expert Committee of the Central Drugs Standard Control Organization.
In addition to eliminating the need for reading glasses, PresVu eye drops also offer the added benefit of lubricating the eyes. The proprietary formula of these eye drops incorporates advanced dynamic buffer technology, ensuring both efficacy and safety for long-term use. Patients can expect consistent results and comfort, making PresVu a promising solution for those struggling with presbyopia.
Dr. Dhananjay Bakhle, a prominent figure in ophthalmology, highlighted the clinical significance of PresVu, emphasizing its non-invasive approach to enhancing near vision without the reliance on reading glasses. ENTOD Pharmaceuticals’ CEO, Nikhil K Masurkar, expressed pride in the years of research that led to the development of PresVu, anticipating its positive impact on millions of individuals.
Starting from the first week of October, PresVu eye drops will be available in pharmacies at an affordable price of Rs.350, offering a convenient and effective solution for individuals aged 40 and above.
Leave a comment